Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Diebold, Kendall [1 ]
Worth, Sarah [2 ]
Bachiashvili, Kimo [2 ]
Vachhani, Pankit [3 ]
Rangaraju, Sravanti [1 ]
Espinoza-Gutarra, Manuel [1 ]
Al-Kadhimi, Zaid [1 ]
Bhatia, Ravi [1 ]
Jamy, Omer [4 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Div Hematol Oncol, Birmingham, AL USA
[4] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
    Weisberg, Ellen
    Sattler, Martin
    Manley, Paul W.
    Griffin, James D.
    ONCOTARGETS AND THERAPY, 2018, 11 : 175 - 182
  • [22] Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
    Menna, Pierantonio
    Marchesi, Francesco
    Cattaneo, Chiara
    Candoni, Anna
    Delia, Mario
    Nadali, Gianpaolo
    Vatteroni, Alessandra
    Pasciolla, Crescenza
    Perrone, Salvatore
    Verga, Luisa
    Armiento, Daniele
    Del Principe, Maria Ilaria
    Fracchiolla, Nicola S. S.
    Salvatorelli, Emanuela
    Lupisella, Santina
    Terrenato, Irene
    Busca, Alessandro
    Minotti, Giorgio
    Pagano, Livio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 1876 - 1885
  • [23] Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments
    Travaglini, Serena
    Gurnari, Carmelo
    Ottone, Tiziana
    Voso, Maria Teresa
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (06) : 569 - 576
  • [24] Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
    Ravandi, Farhad
    Kantarjian, Hagop
    Faderl, Stefan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Koller, Charles
    Pierce, Sherry
    Brandt, Mark
    Kennedy, Deborah
    Cortes, Jorge
    Beran, Miloslav
    LEUKEMIA RESEARCH, 2010, 34 (06) : 752 - 756
  • [25] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [26] BURDEN OF ILLNESS (BOI) OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML)
    Sotak, M. L.
    Marin, M.
    Coombs, J.
    Schiller, G. J.
    Teitelbaum, A.
    VALUE IN HEALTH, 2012, 15 (04) : A101 - A102
  • [27] Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
    Arnan Sangerman, Montserrat
    Fernandez Moreno, Ainhoa
    Garcia Quintana, Antonio
    Garcia-Vidal, Carolina
    Olave Rubio, Maria Teresa
    Tormo Diaz, Maria Del Mar
    Vendranas, Meritxell
    Rodriguez Macias, Gabriela
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 203 - 214
  • [28] Emerging Real-World Midostaurin Treatment Patterns and Outcomes in FLT3-Mutated Acute Myeloid Leukemia at a Comprehensive Cancer Center
    Willis, Connor
    Menon, Jyothi
    Unni, Sudhir
    Au, Trang
    Ndife, Briana
    Joseph, George J.
    Bonifacio, Gaetano J.
    Stein, Eytan M.
    Tantravahi, Srinivas K.
    Shami, Paul J.
    Kovacsovics, Tibor
    Brixner, Diana
    Stenehjem, David Dean
    BLOOD, 2018, 132
  • [29] Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
    McCall, David
    Roth, Michael
    Mahadeo, Kris M.
    Toepfer, Laurie
    Nunez, Cesar
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney
    Yi, Joanna S.
    Cuglievan, Branko
    BLOOD ADVANCES, 2021, 5 (23) : 5215 - 5219
  • [30] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel L.
    Qualtieri, Julianne N.
    Watt, Christopher D.
    Morrissette, Jennifer J. D.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
12345